pharmaphorum16h
FDA expands label for Roche's eye disease implant Susvimo
The new indication adds to the 2021 approval of Susvimo (ranibizumab) for 'wet' or neovascular age-related macular ...
PharmiWeb20h
FDA approves Roche’s Susvimo as the first and only continuous delivery treatment for the leading cause of diabetes-related blindness
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has approved Susvimo® (ranibizumab injection) 100 mg/mL for the treatment of diabetic macular edema ...
Pharmabiz51m
Roche’s Susvimo receives US FDA approval for the treatment of diabetic macular edema
Roche’s Susvimo receives US FDA approval for the treatment of diabetic macular edema: Basel Thursday, February 6, 2025, 11:00 Hrs [IST] Roche announced that the US Food and Drug ...
The Pharma Letter16h
FDA approves Roche’s Susvimo for DME
The US Food and Drug Administration (FDA) has approved Susvimo (ranibizumab injection) 100mg/mL for the treatment of diabetic ...
PipelineReview.com14h
FDA Approves Genentech’s Susvimo as the First and Only Continuous Delivery Treatment for the Leading Cause of Diabetes-Related Blindness
Susvimo is the first and only continuous delivery treatment that offers an alternative to regular eye injections to treat diabetic macular edema (DME) – ...
pharmaphorum15h
JP Morgan Week 2025 – Rick Stewart
At JPM Week 2025 in San Francisco, pharmaphorum editor-in-chief Jonah Comstock met with Rick Stewart, CEO of Achieve Life ...